PsyLabs: Funding, Investors & Team (Sep 2026)
PsyLabs is dedicated to growing and manufacturing psychedelic pharmaceutical ingredients and isolates for research, clinical trials, and pharmaceutical development.
PsyLabs has raised $500k across 1 funding round on record, the most recent an undisclosed round of $500k announced in Apr 2025.
That round is below the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
PsyLabs Company Profile and Key Stats
Latest funding round on record: Apr 2025.
PsyLabs Funding Rounds
PsyLabs Founders and Leadership Team
No contact details are on record for this team yet.
PsyLabs Funding Compared to Other Health Care Startups
PsyLabs' latest round of $500k is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like PsyLabs in Health Care and Cape Town
Companies Similar to PsyLabs
Mia Healthcare is a Hospitals and Health Care firm offering dental services and orthodontic products.
Biovac is a manufacturer contributing towards filling the gap that exists in the lack of African vaccine…
Jembi has expertise in developing eHealth and health information systems (HIS).
Welo Health is a cutting-edge Healthtech Company specializing in offering in-home health services.
VitruvianMD combines biomedical engineering and state-of-the-art artificial intelligence (AI) to deliver…
HealthDart provides digital health, pharmacies, healthcare, and health finance services. They also provide…
Kena Health, the top medical application in South Africa, allows users to conveniently consult with…
Quro Medical is an innovative digital health company pioneering premium hospital-at-home services.
In South Africa, Contro is an online pharmacy and delivery service for sexual health and confidence items. It…
At Strove, we believe that any company is only as healthy as its people. Our mission? To build stronger and…
Aviro Health specializes in design and building digital healthcare solutions.
Ingress Healthcare is changing the face of healthcare through digital tools and solutions - seamlessly…
PsyLabs Funding FAQs
What does PsyLabs do?
PsyLabs is dedicated to growing and manufacturing psychedelic pharmaceutical ingredients and isolates for research, clinical trials, and pharmaceutical development.
How much funding has PsyLabs raised?
PsyLabs has raised $500k across 1 round on record. The most recent is an undisclosed round of $500k announced in Apr 2025.
When did PsyLabs last raise funding?
PsyLabs' most recent funding round on record is an undisclosed round of $500k, announced in Apr 2025.
Who founded PsyLabs?
FundedIQ lists Ivan Avila (Founder) at PsyLabs.
Where is PsyLabs headquartered?
PsyLabs is based in Cape Town, Na - South Africa, South Africa.
How many employees does PsyLabs have?
PsyLabs is in the 11-50 employee band.
How does PsyLabs' funding compare to other Health Care startups?
PsyLabs' latest round of $500k is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's PsyLabs Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for PsyLabs is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.